Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

• Main Authors: Raj Hanvesakul (Author), Badri Rengarajan (Author), Navit Naveh (Author), Anne Boccuti (Author), Julie E Park (Author), Adekemi Adeyemi (Author), Clyde Caisip (Author), Jeroen P Jansen (Author), Florence R Wilson (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Aim: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. Methods: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. Results: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). Conclusion: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.

Item Description

10.57264/cer-2022-0098
2042-6313